Vijayananda Kundapur

Prof. Vijayananda Kundapur


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2015 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
VKVijayananda Kundapur
Vijayananda Kundapur
TETasha Ellchuk
Tasha Ellchuk
SAShahid Ahmed
Shahid Ahmed
VGVinai Gondi
Vinai Gondi

20 November 2024 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
FKFeng-Ming Kong
Feng-Ming Kong
CHChen Hu
Chen Hu
DPDaniel A. Pryma
Daniel A. Pryma
FDFenghai Duan
Fenghai Duan
MMMartha Matuszak
Martha Matuszak
MMMitchell Machtay
Mitchell Machtay
PURPOSE: NRG-RTOG0617 demonstrated a detrimental effect of uniform high-dose radiation in stage III non–small cell lung cancer. NRG-RTOG1106/ECOG-ACRIN6697 (ClinicalTrials.gov identifier: NCT01507428 ), a randomized phase II trial, studied whether midtreatment 18 F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) can guide individualized/adaptive dose-intensified radiotherapy (RT) to improve and predict outcomes in patients with this disease. MATERIALS AND METHODS: Patients fit for concurrent chemoradiation were randomly assigned (1:2) to standard (60 Gy/30 fractions) or FDG-PET–guided adaptive treatment, stratified by substage, primary tumor size, and histology. All patients had midtreatment FDG-PET/CT; adaptive arm patients had an individualized, intensified boost RT dose to residual metabolically active areas. The primary therapeutic end point was 2-year centrally reviewed freedom from local-regional progression (FFLP), defined as no progression in or near the planning target volume and/or regional nodes. FFLP was analyzed on a modified intent-to-treat population at a one-sided Z -test significance level of 0.15. The primary imaging end point was centrally reviewed change in SUV peak from baseline to midtreatment; its association with FFLP was assessed using the two-sided Wald test on the basis of Cox regression. RESULTS: Of 138 patients enrolled, 127 were eligible. Adaptive-arm patients received a mean 71 Gy in 30 fractions, with mean lung dose 17.9 Gy. There was no significant difference in centrally reviewed 2-year FFLP (59.5% and 54.6% in standard and adaptive arms; P = .66). There were no significant differences in protocol-specified grade 3 toxicities, survival, or progression-free survival ( P > .4). Median SUV peak and metabolic tumor volume (MTV) in the adaptive arm decreased 49% and 54%, from pre-RT to mid-RT PET. However, ΔSUV peak and ΔMTV were not associated with FFLP (hazard ratios, 0.997; P = .395 and .461). CONCLUSION: Midtreatment PET-adapted RT dose escalation as given in this study was safe and feasible but did not improve efficacy outcomes.

20 September 2022 in Journal of Clinical Oncology
Verified
Journal Article
Open access
AYAnamaria R. Yeung
Anamaria R. Yeung
SDSnehal Deshmukh
Snehal Deshmukh
AKAnn Klopp
Ann Klopp
KGKaren M. Gil
Karen M. Gil
LWLari Wenzel
Lari Wenzel
DBDeborah W. Bruner
Deborah W. Bruner
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned coprimary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. The purpose of this update was to determine differences in patient-reported chronic toxicity and disease outcomes with intensity-modulated radiation therapy (IMRT) compared with conventional pelvic radiation. Patients with cervical and endometrial cancers who received postoperative pelvic radiation were randomly assigned to conventional radiation therapy (CRT) or IMRT. Toxicity and quality of life were assessed using Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events, Expanded Prostate Cancer Index Composite (EPIC) bowel and urinary domains, and Functional Assessment of Cancer Therapy–General. Between 2012 and 2015, 279 eligible patients were enrolled to the study with a median follow-up of 37.8 months. There were no differences in overall survival ( P = .53), disease-free survival ( P = .21), or locoregional failure ( P = .81). One year after RT, patients in the CRT arm experienced more high-level diarrhea frequency (5.8% IMRT v 15.1% CRT, P = .042) and a greater number had to take antidiarrheal medication two or more times a day (1.2% IMRT v 8.6% CRT, P = .036). At 3 years, women in the CRT arm reported a decline in urinary function, whereas the IMRT arm continued to improve (mean change in EPIC urinary score = 0.5, standard deviation = 13.0, IMRT v –6.0, standard deviation = 14.3, CRT, P = .005). In conclusion, IMRT reduces patient-reported chronic GI and urinary toxicity with no difference in treatment efficacy at 3 years.

1 March 2017 in Clinical Lung Cancer
Verified
Journal Article
Closed access
Anand SwaminathAnand Swaminath
Anand Swaminath
MWMarcin Wierzbicki
Marcin Wierzbicki
SPSameer Parpia
Sameer Parpia
JWJames R. Wright
James R. Wright
TTTheodoros K. Tsakiridis
Theodoros K. Tsakiridis
TWTimothy J. Whelan
Timothy J. Whelan

1 October 2016 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
AKA.H. Klopp
A.H. Klopp
AYA.R. Yeung
A.R. Yeung
SDS. Deshmukh
S. Deshmukh
KGK.M. Gil
K.M. Gil
LWL. Wenzel
L. Wenzel
DBD. Watkins Bruner
D. Watkins Bruner

28 October 2015 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
CCChip Caine
Chip Caine
SDSnehal Deshmukh
Snehal Deshmukh
VGVinai Gondi
Vinai Gondi
MMMinesh p Mehta
Minesh p Mehta
WTWolfgang Tomé
Wolfgang Tomé
LKLisa Kachnic
Lisa Kachnic